Everything below concerns lyophilized powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Retention time supports identity, while the mass spectrum confirms the molecular weight of the intact peptide. Purity is frequently reported as a percentage of total peak area, a figure that depends on the wavelength, column and gradient used. Impurity profiling may also look for truncated sequences, oxidised forms and residual counterions. Amino acid analysis and peptide mapping provide orthogonal confirmation when required.
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
== Side effects == The most common side effects include gastrointestinal disorders, such as dyspepsia, decreased appetite, nausea, vomiting, abdominal pain, diarrhea. Over the course of a 52-week double-blind study to detect the efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes, the most common side effects seen were nausea, diarrhea, and vomiting [20]. Some patients may experience serious adverse reactions: acute pancreatitis (symptoms include persistent severe abdominal pain, sometimes radiating to the back and accompanied by vomiting), hypoglycemia, renal impairment (which may sometimes require hemodialysis). The risk of hypoglycemia is increased if the drug is used in combination with sulfonylureas or insulin. Some more serious side effects include:
=== Optopharmacology === A photoactivatable form of nicotine, which releases nicotine when exposed to ultraviolet light with certain conditions, has been developed for studying nicotinic acetylcholine receptors in brain tissue.
== External links == "Imipenem". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 10 July 2017. "Cilastatin". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 23 January 2017. "Relebactam". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 5 June 2020.
Sources: en.wikipedia.org
Peter S. Tippett (born 1953) is an American physician, researcher, and inventor known for contributions to information security, clinical medicine, and technology. These contributions include the development of the anti-virus program "Corporate Vaccine." Tippett was Vice President of Verizon's Innovations Incubator and Chief Medical Officer for Verizon Enterprise Services from 2009 to 2015. He is currently the Founder and CEO of careMESH Inc.
==== Swan Shiratori ==== Cignian Swan Shiratori (チーニョ星人 白鳥 スワン, Chīnyo Seijin Shiratori Suwan) is Kruger's intellectually and technologically gifted assistant from Planet Cigno who provides the Dekarangers with their arsenal. While she possesses a variant of the SP License called the Swan License (スワンライセンス, Suwan Raisensu), which grants her the ability to transform into the orange-colored Deka Swan (デカスワン, Deka Suwan), she has a personal policy to only do so once every four years, except for emergencies. As Deka Swan, she can perform either the Swan Illusion (スワンイリュージョン, Suwan Iryūjon) attack or the Swan Rainbow (スワンレインボー, Suwan Reinbō) finisher. Swan Shiratori is portrayed by Mako Ishino (石野 真子, Ishino Mako).
==== Llanos and tropical ecology ==== In February 1800, Humboldt and Bonpland departed the Caribbean coast, setting their sights on the Orinoco River. This important northern neighbor of the Amazon promised a gateway into the equatorial jungles, famed for their extraordinary biodiversity and dense tropical vegetation. For Humboldt, the journey offered a long-awaited opportunity to conduct magnetic measurements at latitudes where Earth’s magnetism would differ significantly from what he had found in Europe. The expedition also carried the excitement of possibly confirming the rumored connection between the Orinoco and Amazon or Rio Negro river systems—a geographical mystery that had fascinated explorers for years. The most direct route from Caracas to the Orinoco would have been to cross the southern mountain chain between Baruta and Salamanca, traverse the savannahs of Ocumare, and embark at Cabruta near the Rio Guarico’s mouth. However, this shortcut would have denied the travelers the chance to survey the most fertile and cultivated regions of the province—the valleys of Aragua—along with valuable opportunities to measure the elevation of the coastal mountain chain by barometer and to descend the Rio Apure to its meeting point with the Orinoco. From Puerto Cabello, Humboldt and Bonpland made their way across the coastal ranges and llanos towards Lake Valencia. The heat was so intense that they often rode at night to avoid the sun’s punishing rays.
Sources: en.wikipedia.org
Glutamate is a key compound in cellular metabolism. Dietary proteins are digested into amino acids, which can be absorbed into the bloodstream or serve as metabolic fuel within the intestinal lining cells (enterocytes). A key process in amino acid degradation is transamination, in which the amino group of an amino acid is transferred to an α-ketoacid, typically catalysed by a transaminase. The reaction can be generalised as such:
== History == In 1958, James (Jim) Logan Waters founded Waters Associates in an office in the basement of a police station in Framingham, Massachusetts. Early products included a boiler feedwater flame photometer, a balloon hydrometer, a nerve gas detector, a lab refractometer and process control refractometers. Having asked Waters to design a refractometer in 1961, Dow Chemical had designed a method of analyzing polymers using gel columns. Waters negotiated an exclusive license to the patent, paying $10,000 plus a 10% royalty. In 1962, Hardie Sheppard provided the company with $150,000, its first external financing raise. In 1963, Waters’ produced its first five gel permeation chromatography instruments, selling three to Dow Chemical, one to BFGoodrich, and one to Esso. Dow Chemical then invested $400,000 in Waters. In 1965, interest surged after Waters sponsored a symposium where scientists presented the results of using Waters equipment. In 1966, Dow converted its royalty receivable into equity in Waters. In 1967, the company introduced the ALC 100, the first Waters LC system. It was a benchtop system equipped with a Milton Roy pump, syringe injection, and two detectors: a Waters differential refractometer and a UV detector from Laboratory Data Control. In 1969, Dimitri D’Arbeloff, then president of Millipore Corporation, joined the board of directors; Millipore's venture capital subsidiary made a $600,000 equity investment in Waters and provided the company with marketing expertise. By 1972, Dow Chemical had invested $700,000 in the company and owned a 20% stake.
== Therapeutic application == Thymosin α1 is approved in some countries for the treatment of Hepatitis B and C, and it is also used to boost the immune response in the treatment of other diseases. The synthetic version of Thymosin α1 is known as Thymalfasin and is sold under the brand name Zadaxin. Thymosin α1 is usually administered by subcutaneous injection.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
The dry powder is more stable during transport and storage than a solution. It also allows a known amount of material to be reconstituted at a chosen concentration.